Ongericimab Injection Reducing Recurrence of Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 4810 participants.

Also called NCT07242599

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,810 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07242599
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07242599. Randomized; single masking; primary purpose treatment. Start 2026-04-22 (anticipated); primary completion 2029-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ongericimab Injection Reducing Recurrence of Ischemic Stroke
Acronym
ORIS
Condition
Ischemic Cerebral Infarction
Intervention (Combination product)
High target group
Intervention (Combination product)
Low target group
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct07242599
Content hash
1efc35a1887b8a4033521b43fc74fc536bfc4252540a83d9542c6421c2201904